Exclusive Thailand Commercialisation Agreement Secured
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Memphasys Ltd has announced an exclusive three-year commercial distribution agreement with IVF Envimed Co., Ltd. for the Felix™ sperm separation system in Thailand, a significant market for assisted reproductive technology. Memphasys anticipates that revenue will begin following the expected Thai FDA regulatory approval within a few months.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Memphasys
- UK Market Entry & Acceleration of Commercial Expansion
- Successful $1.2M Placement and Convertible Note Extended
- Memphasys Executes Supply Agreement with Monash IVF Group
- South-East Asian Commercialization Agreement Secured
- ITL Orders 1000 Felix Cartridges Across MENA Markets
Later from Memphasys
- European Commercial Roll-out continues with Poland Agreement
- Felix Registration Achieved in Vietnam and Cartridge Order
- Felix Early Thai FDA Approval, Commercial Launch Accelerates
- EUR526,500 Nordic Agreement Expands Felix European Footprint
- Felix Registration Achieved in Turkey, Sales Commence
Follow Memphasys into a list and get an email when it puts out news.
Follow Memphasys